Overview

A Randomized Study of Sativex on Cognitive Function and Mood: Multiple Sclerosis Patients

Status:
Completed
Trial end date:
2013-05-01
Target enrollment:
Participant gender:
Summary
A study to compare the change in cognitive performance and psychological status of patients with spasticity due to Multiple Sclerosis when treated with Sativex or placebo, added to existing anti-spasticity therapy over a period of 48 weeks. Secondary objectives were to evaluate the effect of Sativex on mood and spasticity and to assess the safety and tolerability of Sativex.
Phase:
Phase 4
Details
Lead Sponsor:
GW Pharmaceuticals Ltd.
Treatments:
Nabiximols